B & J Group, a Morrisville, PA contract filler of OTC hand sanitizer, was cited by FDA for skipping finished-product and ingredient testing.
What happened
FDA did not inspect the facility; instead it reviewed records the company submitted in response to a request for records under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, sent in January and February 2022. In those records, B & J Group said finished-product testing was "Done by customer," raw material identity testing was "Not Applicable," and batch production records were "Maintained by customers." FDA said this shows the company released hand sanitizer without evidence it met specifications and without verifying incoming ingredients such as ethanol or isopropyl alcohol.
What FDA found
The company released each batch of hand sanitizer without laboratory testing to confirm the identity and strength of the active ingredients or to show the product was free of harmful microorganisms.
21 CFR 211.165(a) and (b)The company did not run at least one identity test on each incoming lot of ingredients, including ethanol and isopropyl alcohol, which can be contaminated with toxic methanol.
21 CFR 211.84(d)(1)The company had no written production and process control procedures and kept no batch production records of its own, so it could not show its process makes a consistent product.
21 CFR 211.100(a)
What FDA wants
FDA tells the company to fix the violations promptly and to reply in writing within 15 working days describing what it has done and how it will prevent recurrence. The reply must include test methods and specifications, a plan to test reserve samples of all unexpired US-distributed batches, a component testing plan, a documentation corrective action plan, and a full reconciliation of all hand sanitizer distributed.
Who should pay attention
- brands that hire B & J Group as a contract filler for hand sanitizer
- distributors and retailers selling OTC hand sanitizer filled by contractors
- quality teams at contract manufacturers and fillers of OTC drug products
This is a summary. Read the original letter on fda.gov.